Holen Sie sich die Stockscreener-App
30.70
0.81%
-0.25
Handel nachbörslich:
31.32
0.62
+2.02%
Schlusskurs vom Vortag:
$30.95
Offen:
$30.91
24-Stunden-Volumen:
1.17M
Relative Volume:
0.58
Marktkapitalisierung:
$3.12B
Einnahmen:
$352.57M
Nettoeinkommen (Verlust:
$-143.01M
KGV:
-16.96
EPS:
-1.81
Netto-Cashflow:
$-153.40M
1W Leistung:
-0.86%
1M Leistung:
+9.72%
6M Leistung:
+41.34%
1J Leistung:
+18.49%
1-Tages-Spanne:
$30.32
$32.26
1-Wochen-Bereich:
$30.16
$35.34
52-Wochen-Spanne:
$13.53
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
Firmenname
Beam Therapeutics Inc
Sektor
Branche
Telefon
857-327-8775
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie BEAM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
30.70 | 3.14B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-09 | Eingeleitet | Jefferies | Buy |
| 2025-03-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-10 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-08 | Herabstufung | Jefferies | Buy → Hold |
| 2023-10-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Eingeleitet | Citigroup | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-01-05 | Eingeleitet | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-24 | Fortgesetzt | Stifel | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Redburn | Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-08-05 | Eingeleitet | William Blair | Outperform |
| 2020-03-02 | Eingeleitet | Barclays | Overweight |
| 2020-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-03-02 | Eingeleitet | Jefferies | Buy |
| 2020-03-02 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Christine Bellon Sells 1,371 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Shares Down 7.6%Here's Why - MarketBeat
Sickle Cell Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics, Graphite Bio, Roche - Barchart.com
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35 - 富途资讯
William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating - 富途资讯
Cathie Wood Sells Beam Therapeutics Stock, Buys WeRide and Tempus AI - Blockonomi
Cathie Wood Sells $5 Million Beam Therapeutics Stock, Buys WeRide and Tempus AI - CoinCentral
Campbell & CO Investment Adviser LLC Lowers Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Is Beam Therapeutics Inc forming a breakout pattern2025 Key Highlights & Free Community Consensus Stock Picks - baoquankhu1.vn
Beam soars 22% as FDA signs off on its ambitious gene-editing plan - MSN
Growth Report: Is Butterfly Network Inc Equity Warrant stock a buy or sellMarket Sentiment Summary & Advanced Technical Signal Analysis - baoquankhu1.vn
cathie wood’s ARK sells beam therapeutics stock, buys weride and tempus ai By Investing.com - Investing.com India
cathie wood’s ARK sells beam therapeutics stock, buys weride and tempus ai - Investing.com
Beam Therapeutics (NASDAQ:BEAM) Trading 11.1% HigherWhat's Next? - MarketBeat
Cathie Wood Dumps Beam Therapeutics, Loads Up on Netflix Stock - Blockonomi
Cathie Wood’s ARK ETFs Buy Netflix, Sell Beam Therapeutics in Latest Moves - CoinCentral
Beacon trial data makes Beam Therapeutics (BEAM) an attractive buy - MSN
Insider Sell: Bethany Cavanagh Sells Shares of Beam Therapeutics Inc (BEAM) - GuruFocus
Beam Therapeutics (BEAM) Receives Rating Update with Raised Pric - GuruFocus
Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway By Investing.com - Investing.com India
Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway - Investing.com Nigeria
Discipline and Rules-Based Execution in BEAM Response - Stock Traders Daily
Insider Selling: Beam Therapeutics (NASDAQ:BEAM) Insider Sells 18,629 Shares of Stock - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.1%Should You Sell? - MarketBeat
Earnings Report: Is Beam Therapeutics Inc a cyclical or defensive stock2025 EndofYear Setup & Accurate Intraday Trade Tips - baoquankhu1.vn
Aug Intraday: What is Rapid7 Incs 5 year growth outlookPortfolio Return Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Beam Therapeutics stock maintains Buy rating at H.C. Wainwright on FDA alignment - Investing.com Nigeria
Gene editing trials in sickle cell advance as Beam builds $1.1B cash - Stock Titan
Institution Moves: Will BHRPRD announce a stock splitPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
Sumitomo Mitsui Trust Group Inc. Has $117.24 Million Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
BEAM: Base editing programs advance toward approval, backed by strong data, funding, and scalable technology - TradingView — Track All Markets
BEAM: Predictable gene editing advances drive pivotal programs and commercial readiness into 2029 - TradingView
Buyback Watch: How does AHTPRI score in quality rankingsQuarterly Market Summary & Growth Focused Entry Point Reports - baoquankhu1.vn
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises - sharewise.com
Beam Therapeutics: Pivoting From Platform To Execution Stage (NASDAQ:BEAM) - Seeking Alpha
April 17th Options Now Available For Beam Therapeutics - Nasdaq
Beam Therapeutics (BEAM) to Submit Biologics License Application for Risto-cel by End of 2026 - Intellectia AI
Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029 - Yahoo Finance
Beam Therapeutics stock today: BEAM edges lower premarket after FDA alignment sparks 22% rally - TechStock²
Beam Therapeutics Price Target Upgrade Signals Positive Outlook - timothysykes.com
Gene Editor Soars To 10-Month High On Bullish FDA News - Investor's Business Daily
Beam Therapeutics (NASDAQ:BEAM) Shares Gap UpTime to Buy? - MarketBeat
Beam Therapeutics stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Nigeria
Key facts: Beam Therapeutics seeks FDA approval for BEAM-302 therapy - TradingView — Track All Markets
Beam Therapeutics Stock Surges: What's Driving The Sudden Jump? - Benzinga
Beam Therapeutics (BEAM) Shares Surge Nearly 28% - GuruFocus
Beam Therapeutics stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise - Stocktwits
Beam Therapeutics Advances Genetic, Hematology Pipeline, Extends Cash Runway to 2029; Shares Rise - marketscreener.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Beam Therapeutics (BEAM) Sees Positive Developments in Regulator - GuruFocus
Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):